Surgery Partners (SGRY)
(Real Time Quote from BATS)
$24.07 USD
-0.77 (-3.10%)
Updated Apr 26, 2024 10:36 AM ET
3-Hold of 5 3
B Value B Growth F Momentum B VGM
Price, Consensus and EPS Surprise
SGRY 24.07 -0.77(-3.10%)
Will SGRY be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for SGRY based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for SGRY
SGRY vs. DOCS: Which Stock Should Value Investors Buy Now?
Surgery Partners (SGRY) Upgraded to Buy: What Does It Mean for the Stock?
SGRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Believe Surgery Partners (SGRY) Could Rally 39.04%: Here's is How to Trade
Company News for Feb 27, 2024
The Zacks Analyst Blog Highlights Microsoft, Amazon.com, Surgery Partners, Nvidia and Occidental Petroleum
Other News for SGRY
Baron Health Care Fund Q1 2024 Shareholder Letter
Surgery Partners, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Details
ClearBridge Select Strategy Q1 2024 Portfolio Manager Commentary
Surgery Partners Inc Refinances Debt and Secures New Funding
Surgery Partners: A Buy Rating Amidst Underperformance and Growth Potential